Whiskey, as I have a Bulleit to ease the pains of my day, your post is the best one I have read in a long time with the sound logic of how the CEO is trying to protect the Anavex franchise.
As to Biogen, if there is a product that can reverse and defeat the "Barbarians at your gate" (think Pope Leo the Great and Attila) and saves your $8-9B annual sales stream with 80%+ margins, why would you wait for others to see the value of that product when you have had first look. You make sure you are first in line with a deal that both parties can live and work with. As an example, BMS did not wait around when it bought Mederax on the cheap @ 3B.
Biogen's problem is: Anavex is NOT for sale, but willing to deal/partner..